Drug intelligence / Profile preview

rovazolac

Development stage: Phase 2
Lead developer: Ralexar Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

Rovazolac is a small molecule drug under investigation as a topical treatment for moderate atopic dermatitis. It acts as an agonist of the liver X receptor (LXR), a nuclear receptor involved in lipid metabolism and inflammation. By activating LXR, rovazolac is predicted to promote regeneration and maintenance of the dermal barrier and reduce inflammatory insult to the skin. The drug was initially developed by Alexar Therapeutics and has reached Phase 2 clinical trials for atopic dermatitis[1][2][3][5][8].

Other names: 1454288-88-0rovazolac [INN]595566-61-3

Targets

LXRB (Liver X receptor beta)NR1H3 (Liver X receptor beta)

Beyond the preview

Go deeper on rovazolac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rovazolac.

Explore the full profile